<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Classifying asthma severity and initiating treatment in youths greater than or equal to 12 years of age and adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Classifying asthma severity and initiating treatment in youths greater than or equal to 12 years of age and adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Classifying asthma severity and initiating treatment in youths greater than or equal to 12 years of age and adults</div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup><colgroup span="5" width="18%"></colgroup> <tbody> <tr> <td class="subtitle1" colspan="2" rowspan="3">Components of severity</td> <td class="subtitle1" colspan="4">Classification of asthma severity (≥12 years of age)</td> </tr> <tr> <td class="subtitle2" rowspan="2">Intermittent</td> <td class="subtitle2" colspan="3">Persistent</td> </tr> <tr> <td class="subtitle3">Mild</td> <td class="subtitle3">Moderate</td> <td class="subtitle3">Severe</td> </tr> <tr> <td class="divider_bottom" rowspan="5"> <p>Impairment</p> <p>Normal FEV<sub>1</sub>/FVC:</p> <p>8 to 19 years 85%</p> <p>20 to 39 years 80%</p> <p>40 to 59 years 75%</p> 60 to 80 years 70%</td> <td>Symptoms</td> <td>≤2 days/week</td> <td>&gt;2 days/week but not daily</td> <td>Daily</td> <td>Throughout the day</td> </tr> <tr> <td>Nighttime awakenings</td> <td>≤2x/month</td> <td>3 to 4x/month</td> <td>&gt;1x/week but not nightly</td> <td>Often 7x/week</td> </tr> <tr> <td>Short-acting beta<sub>2</sub>-agonist use for symptom control (not prevention of EIB)</td> <td>≤2 days/week</td> <td>&gt;2 days/week but not daily, and not more than 1x on any day</td> <td>Daily</td> <td>Several times per day</td> </tr> <tr> <td>Interference with normal activity</td> <td>None</td> <td>Minor limitation</td> <td>Some limitation</td> <td>Extremely limited</td> </tr> <tr class="divider_bottom"> <td>Lung function</td> <td> <ul> <li>Normal FEV<sub>1</sub> between exacerbations</li> <li>FEV<sub>1</sub> ≥80% predicted</li> <li>FEV<sub>1</sub>/FVC normal</li> </ul> </td> <td> <ul> <li>FEV<sub>1</sub> ≥80% predicted</li> <li>FEV<sub>1</sub>/FVC normal</li> </ul> </td> <td> <ul> <li>FEV<sub>1</sub> ≥60 but &lt;80% predicted</li> <li>FEV<sub>1</sub>/FVC reduced 5%</li> </ul> </td> <td> <ul> <li>FEV<sub>1</sub> &lt;60% predicted</li> <li>FEV<sub>1</sub>/FVC reduced &gt;5%</li> </ul> </td> </tr> <tr> <td class="divider_bottom" rowspan="4">Risk</td> <td class="divider_bottom" rowspan="4"><strong>Exacerbations requiring oral systemic glucocorticoids</strong></td> <td><strong>0 to 1/year (see footnote)</strong></td> <td colspan="3"><strong>≥2/year (see footnote)</strong></td> </tr> <tr> <td colspan="4"><strong>Consider severity and interval since last exacerbation</strong></td> </tr> <tr> <td colspan="4"><strong>Frequency and severity may fluctuate over time for patients in any severity category</strong></td> </tr> <tr class="divider_bottom"> <td colspan="4"><strong>Relative annual risk of exacerbations may be related to FEV<sub>1</sub></strong></td> </tr> <tr> <td colspan="2" rowspan="3">Recommended step for initiating treatment</td> <td rowspan="2">Step 1</td> <td rowspan="2">Step 2</td> <td>Step 3</td> <td>Step 4 or 5</td> </tr> <tr> <td colspan="2">And consider short course of oral systemic glucocorticoids</td> </tr> <tr> <td colspan="4">In two to six weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.</td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>Assessing severity and initiating treatment for patients who are not currently taking long-term control medications.</strong> The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs. Level of severity is determined by assessment of both impairment and risk. Assess impairment domain by patient's/caregiver's recall of previous two to four weeks and spirometry. Assign severity to the most severe category in which any feature occurs. At present, data are inadequate to correlate frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had ≥2 exacerbations requiring oral systemic glucocorticoids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.</div><div class="graphic_footnotes">FEV<sub>1</sub>: forced expiratory volume in one second; FVC: forced vital capacity; ICU: intensive care unit.</div><div class="graphic_reference">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id="graphicVersion">Graphic 58247 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
